Establishment Labs flagged new clinical and scientific breast tissue preservation data already presented at the 11th World Symposium on Ergonomic Implants.
Findings supported the rationale for its minimally invasive platform, citing early- and mid-term clinical experience, including initial published U.S. multicenter use.
Management pointed to market momentum, citing 11% growth in U.S. breast augmentation procedures, to frame demand for its approach.
Product launch plan broadened Mia and Preservé with new sizes and tools, aimed at expanding the addressable patient pool.
ESTA•
